Teva Pharmaceutical Industries (NYSE:TEVA) Receives “Overweight” Rating from Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research note released on Thursday morning,Benzinga reports. They currently have a $42.00 target price on the stock, up from their prior target price of $41.00.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Barclays boosted their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Jefferies Financial Group boosted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Truist Financial boosted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Scotiabank upped their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.56.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $35.03 on Thursday. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The business’s 50 day moving average price is $31.15 and its 200-day moving average price is $29.33. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35. The stock has a market cap of $40.28 billion, a P/E ratio of 26.34, a P/E/G ratio of 3.12 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 44.86% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Richard D. Francis sold 442,935 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $32.36, for a total value of $14,333,376.60. Following the transaction, the chief executive officer directly owned 642,099 shares of the company’s stock, valued at approximately $20,778,323.64. This represents a 40.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total value of $11,633,048.40. Following the completion of the transaction, the executive vice president directly owned 57,478 shares in the company, valued at $1,933,559.92. This trade represents a 85.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 920,901 shares of company stock worth $30,056,789 in the last three months. Corporate insiders own 0.54% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Phoenix Financial Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after purchasing an additional 3,533,800 shares in the last quarter. National Pension Service increased its stake in shares of Teva Pharmaceutical Industries by 24.2% in the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board increased its stake in shares of Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after purchasing an additional 69,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after purchasing an additional 4,306,363 shares in the last quarter. Finally, Teacher Retirement System of Texas increased its stake in shares of Teva Pharmaceutical Industries by 11.2% in the 3rd quarter. Teacher Retirement System of Texas now owns 697,574 shares of the company’s stock worth $14,091,000 after purchasing an additional 69,994 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings and revenue beat — Teva reported Q1 results above estimates with branded drugs (Austedo, Ajovy, Uzedy) driving growth and net income/earnings gains, which sparked the immediate market rally. TEVA Q1 Earnings Top Estimates
• Positive Sentiment: Multiple analyst upgrades and higher price targets — Truist, UBS, JPMorgan and Piper Sandler raised price targets (Truist to $45, UBS to $42, JPMorgan to $40, Piper to $42) and reiterated buy/overweight views, signaling expected upside and supporting the stock’s momentum. Analyst Notes (Benzinga) Truist Note (TickerReport)
• Positive Sentiment: Strategic acquisition — Teva agreed to buy Emalex Biosciences (up to ~$900M, $700M cash upfront) to add ecopipam (NDA?ready for pediatric Tourette’s) to its neuroscience pipeline, boosting growth optionality beyond generics. Teva to Acquire Emalex Biosciences
• Positive Sentiment: Sustainability-linked bond targets met — Teva said it exceeded all targets tied to ~$7.5B of sustainability-linked bonds, which reduces ESG-related execution risk and may appeal to ESG-focused investors. 2025 Healthy Future Report
• Positive Sentiment: Signs of institutional bullishness — Large call-option activity and reported interest from private capital (e.g., Blackstone financing coverage) indicate increased investor conviction and speculative/hedging flows into the shares. Blackstone Coverage
• Neutral Sentiment: Industry positioning and market analysis — Reports list Teva among leaders in the oral solid dosage contract manufacturing market, reflecting scale and potential contract-manufacturing tailwinds over the medium term. Oral Solid Dosage Market Analysis
• Neutral Sentiment: Product-level wins — Uzedy U.S. net sales rose to $63M in Q1 (strong growth rate but still early in scale), supporting the narrative of branded recovery even as the company rebalances its portfolio. UZEDY Sales Report
• Negative Sentiment: Generics pressure and localized revenue declines — Management flagged weaker generics performance and a slight revenue decline in local currency (and continued pressure from lenalidomide generic dynamics), which remains a structural risk for margins and growth if branded momentum slows. Q1 Results & Commentary

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.